Other Events ·
Lineage Cell Therapeutics, Inc. withdrew its application for a Clinical Trial (CLIN2) award from the California…
LCTXLineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. withdrew its application for a Clinical Trial (CLIN2) award from the California Institute for Regenerative Medicine (CIRM) on June 9, 2026, following feedback on the application. The company stated the withdrawal will not affect the ongoing DOSED clinical study evaluating the safety and utility of a spinal cord delivery device for administering OPC1 to treat spinal cord injuries. Additionally, the company held its annual meeting of shareholders on June 10, 2026, where seven directors were elected, the appointment of Baker Tilly US, LLP as independent auditor was ratified, and advisory executive compensation was approved. Lineage Cell Therapeutics is a biotechnology company focused on developing cell therapies for spinal cord injuries.